***Background.*** *Acinetobacter baumannii* is an established nosocomial pathogen in many medical centers worldwide. The spread of multidrug resistant strains of *A. baumannii* has been especially problematic.

***Methods.*** During a three month surveillance study conducted November 2013 -- January 2014, all unique patient isolates of *A. baumannii* were gathered from 11 hospitals in New York City. Susceptibility testing was performed by CLSI methods; isolates with a meropenem MIC of ≤ 2 µg/ml were considered susceptible. All isolates were screened by PCR for the presence of carbapenemases. Select isolates underwent genetic fingerprinting using ERIC-2 primers. Findings were compared to a similar surveillance study conducted in 2009.

***Results.*** A total of 158 isolates of *A. baumannii* were gathered from the 11 hospitals. Overall susceptibility rates include: 72% to amikacin, 30% to ciprofloxacin, 94% to polymyxin B, 34 % to ceftazidime, and 31% to meropenem. 58 isolates possessed *bla*~OXA23~, two *bla*~OXA24~, and one *bla*~KPC~.

Nine hospitals participated in a similar surveillance study conducted in 2009. For these 9 hospitals, there was a marked decline in the total number of isolates reported (from 252 in 2009 to 122 in 2013-2014; Table). However, there was a marked increase in the number of isolates carrying *bla*~OXA-23~ (from 8 to 48). For these 8 hospitals, the percentage of meropenem-resistant isolates that possessed *bla*~OXA23~ increased from 5% in 2009 to 58% in 2013-2014.

Genetic fingerprinting of 15 OXA-23-carrying isolates from 8 hospitals revealed that 9 belonged to a single strain.

               Total number of isolates (number with *bla*~OXA23~)   
  ------------ ----------------------------------------------------- -----------
               2009                                                  2013-2014
  Hospital A   72 (4)                                                32 (19)
  Hospital B   18 (2)                                                7 (2)
  Hospital C   5 (2)                                                 4 (0)
  Hospital D   21 (0)                                                4 (0)
  Hospital E   15 (0)                                                7 (2)
  Hospital F   24 (1)                                                16 (1)
  Hospital G   51 (0)                                                32 (18)
  Hospital H   37 (1)                                                14 (6)
  Hospital I   9 (0)                                                 6 (0)
  Total        252 (8)                                               122 (48)

***Conclusion.*** Since 2009, there has been a reduction in the prevalence of carbapenem-resistant *A. baumannii* at hospitals in New York City. However, dissemination of strains carrying *bla*~OXA23~ has clearly increased in several medical centers.
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